Karachi: GlaxoSmithKline Pakistan Limited has announced a forthcoming virtual meeting of its Board of Directors to evaluate the company's financial results for the half-year period ending June 30, 2026. The meeting is set to take place on August 25, 2026, at 10:30 a.m., originating from the company's head office located at 35 Dockyard Road, West Wharf, Karachi.

The company has imposed a closed trading period starting from August 18, 2026, and extending through August 25, 2026. This action aligns with clause 5.6.4 of the Rule Book of the Pakistan Stock Exchange. During this interval, key stakeholders, including directors, the Chief Executive Officer, Chief Financial Officer, Company Secretary, substantial shareholders, and other executives, along with their spouses, are prohibited from directly or indirectly engaging in transactions involving the company's shares.

According to information available from the Pakistan Stock Exchange (PSX), the closed period is a standard regulatory practice aimed at preventing insider trading and ensuring fair market conduct.

Employees of GlaxoSmithKline Pakistan Limited have been duly informed of this closed period to comply with regulatory requirements. The company continues to adhere to the rules and standards set forth by the PSX, maintaining transparency and integrity in its financial reporting and governance practices.